GLP-1 Drugs Quietly Reshape How Americans Shop for Food, Study Finds
This article first appeared on GuruFocus. Weight loss may be just one side effect of GLP-1 drugs. A…
Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access
This article first appeared on GuruFocus. Weight-loss drugs known as GLP-1s are increasingly reshaping healthcare and the pharmaceutical…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here,…
High-Dose Wegovy Takes Aim at Lilly’s Zepbound
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) said its high-dose version of Wegovy has received a…
Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks – National
Negotiations that could have led to coverage of weight-loss drug Wegovy under Canadian public health plans are not…
Weight-Loss Drug Zepbound Cost Drops To $299 A Month After Trump Deal
Topline Eli Lilly on Monday lowered the cost of Zepbound after the pharmaceutical giant and Ozempic maker Novo…
Ozempic Prices Lowered After Trump Deal
Topline Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment…
GLP-1 goliath updates demand for top weight loss drug
Novo Nordisk reported Q3 2025 earnings on November 5, showing continued strong demand for its weight-loss drug Wegovy,…
Massive sales for weight loss drugs spur Eli Lilly’s Q3
As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn…